Abstract library

20 results for "Moreno-Ríos".
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#447 SOMscan: Towards a Ga-68-labeled Pan-Somatostatin PET Imaging Probe Based on SOM230 (Pasireotide)
Introduction: The somatostatin receptor subtype sst2 is largely expressed on neuroendocrine tumors. However, current clinical studies indicate that the subtypes sst1, 3, 5 are of substantial relevance as well.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Melpomeni Fani
Authors: Fani M, Braun F, Mann A, Kiewer A, ...
Keywords: SOM230, Ga-68, PET imaging
#1384 Gastroenteropancreatic Neuroendocrine Tumors. Ten Year Experience at Instituto Oncologico Nacional. Panama 2004-2015.
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasm with a rising incidence worldwide.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD, MSc Omar Castillo-Fernandez
#1399 High Grade Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). Instituto Oncologico Nacional. Panama City, Panama. 2004-2015
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare and complex neoplasms that present many clinical challenges. High grade at diagnosis is an adverse prognostic factor
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Joel Moreno-Ríos
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...
#306 The Risk of Metachronous Cancers In Patients with Small Intestinal Carcinoid Tumors
Introduction: Small intestinal carcinoids (SIC) are the most common small bowel malignancies. No population-based study has examined the risk for, and prognosis of, metachronous cancers and SICs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Michelle Kim
Authors: Amin S, Warner R R, Itzkowitz S, Kim M, ...
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S, ...
#1061 Transcatheter Arterial Chemoembolization for Unresectable Metastatic Hepatic Lesions of Pancreatic Neuroendocrine Tumors
Introduction: The blood supply of metastatic hepatic neuroendocrine tumors is mainly supplied by hepatic arteries. For unresectable metastatic NETs, selective embolisation of the hepatic arteries may be therapeutic.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Bao Xin
Authors: Xin B, Lou W, Ji Y, Liu L X, ...
Keywords: pnet, hepatic lesion, tace
#1112 Second Primary Malignancies in Patients with Neuroendocrine Tumors
Introduction: Numerous studies have demonstrated an elevated incidence of second primary malignancies (SPM) in patients with neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
#1192 Clinical Characteristics and Overall Survival of Large Cell Neuroendocrine Carcinoma (LCNEC) Compared to Other Subtypes of Lung Cancer: Results of a Population-based Registry
Introduction: LCNEC is a rare non-small cell lung cancer subtype and clinical behavior is unclear.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: LCNEC, lung
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.